台灣臨床試驗主持人資料庫|TPIDB

2017-12-08 - 2023-02-01

Phase III

A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age

Condition/Disease

Type 2 Diabetes Mellitus in Pediatric Patients
Test Drug

Dapagliflozin / Saxagliptin

Participate Sites
3Sites

Recruiting2Sites

Suspended1Sites

牛道明

Taipei Veterans General Hospital

2017-02-28 - 2020-02-11

Phase II

Condition/Disease
Test Drug

Participate Sites
2Sites

Terminated2Sites

陳育民

Taipei Veterans General Hospital

Division of Thoracic Medicine

2016-01-06 - 2018-12-31

Phase II

Condition/Disease
Test Drug

Participate Sites
2Sites

Terminated2Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2019-08-09 - 2022-06-30

Phase III

A Phase 3, Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis

Condition/Disease

Secondary Hyperparathyroidism
Test Drug

KHK7580

Participate Sites
10Sites

Terminated10Sites

唐德成

Taipei Veterans General Hospital

Division of Nephrology

2018-12-15 - 2022-09-27

Phase II

An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer

Condition/Disease

Non-small Cell Lung Cancer
Test Drug

M7824

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

沈佳儀

Taipei Veterans General Hospital

Division of Thoracic Medicine

2015-02-01 - 2017-06-30

Phase II

A MULTIPLE-CENTER, RANDOMIZED, PARTIALLY DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTIVIRAL EFFECTS OF 12-WEEK TREATMENT WITH RO6864018 IN VIROLOGICALLY SUPPRESSED ENTECAVIR TREATED PATIENTS WITH HEPATITIS B VIRUS INFECTION

Condition/Disease

HEPATITIS B VIRUS(HBV) INFECTION
Test Drug

RO6864018

Participate Sites
2Sites

Terminated2Sites

黃怡翔

Taipei Veterans General Hospital

Digestive System Department

2014-12-30 - 2019-12-31

Phase III

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)

Condition/Disease

major adverse cardiovascular event, MACE
Test Drug

Epanova®

Participate Sites
7Sites

Terminated6Sites

江晨恩

Taipei Veterans General Hospital

賴文德

Kaohsiung Municipal Gangshan Hospital

未分科

2016-06-01 - 2019-05-31

Phase I

A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumors

Condition/Disease

Advanced Tumors
Test Drug

BGB-A317

Participate Sites
6Sites

Terminated6Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

侯明模

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-03-14 - 2025-05-13

Phase II

An Open-Label, Multicenter, Global Phase 2 Basket Study of for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Entrectinib Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Condition/Disease

Locally Advanced or Metastatic Solid Tumors that Entrectinib Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Test Drug

Entrectinib

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

羅永鴻

Taipei Veterans General Hospital

2015-08-01 - 2017-12-31

Phase I

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study To evaluate The Safety, Tolerability, And Immunogenicity Of INO-1800 Alone Or in Combination With INO-9112 Delivered IM Followed By Electroporation In Select Nucleos(t)ide Analogue-Treated, HBeAG-Positive, Chronic Hepatitis B Patients

Condition/Disease

Chronic Hepatitis B
Test Drug

INO-1800 and INO-9112

Participate Sites
6Sites

Terminated5Sites

黃怡翔

Taipei Veterans General Hospital

Digestive System Department

莊萬龍

Kaohsiung Municipal Gangshan Hospital

未分科

Search Result

List